Abstract
Circular RNAs (circRNAs) comprise a class of noncoding RNA molecules that play an important role in several normal cellular functions, as well as tumorigenesis in humans. However, the expression patterns and biological functions of circRNAs in ovarian cancer (OC) remain unclear. Therefore, we investigated the expression profiles and biological functions of certain circRNAs in OC tumor tissues. The expression of three circRNAs (VPS13C-has-circ-001567, RAD50-has-circ-00718, and SPECC1-has-circ-000013) was detected by real-time polymerase chain reaction in OC cell lines, and also in tumor and pericarcinous tissues obtained from 20 patients with OC. The function of VPS13C-has-circ-001567 in SKOV3 and OV-1063 cells was investigated by knockdown of VPS13C-has-circ-001567 and then analyzing any resultant effects on the cell cycle, cell proliferation, apoptosis, and cell invasion ability. E-cadherin and N-cadherin expressions were analyzed by immunofluorescence and western blotting. Finally, the tumorigenicity of OC cells was assessed in nude mice. The results showed that VPS13C-has-circ-001567 was expressed at significantly higher levels in OC tumor tissues compared with pericarcinous tissues, and this overexpression was associated with tumor node metastasis stage and lymph node metastasis. We found that knockdown of VPS13C-has-circ-001567 significantly promoted apoptosis and inhibited the proliferation of SKOV3 and OV-1063 cells in vitro. Knockdown of VPS13C-has-circ-001567 led to cell cycle arrest at G1 phase and decreased the percentage of S1 phase cells. Additionally, knockdown of VPS13C-has-circ-001567 decreased the invasion ability of SKOV3 and OV-1063 cells, and also changed the levels of E-cadherin and N-cadherin expressions. Knockdown of VPS13C-has-circ-001567 significantly reduced the tumorigenicity of OC cells. Taken together, our results suggest that VPS13C-has-circ-001567 plays a role in the development of OC and might be a prognostic marker and therapeutic target for OC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
